WallStreetZenWallStreetZen

NASDAQ: GALT
Galectin Therapeutics Inc Stock Ownership - Who owns Galectin Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Galectin Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Kary EldredDirector2026-02-06300$2.70
$810.00Buy
Richard E. UihleinDirector2026-01-1613,158$3.04
$40.00kBuy
Joel LewisPresident and CEO2026-01-0637,698$3.58
$134.85kSell
Jack W. CallicuttChief Financial Officer2026-01-0620,354$3.67
$74.70kSell
Khurram JamilChief Medical Officer2026-01-0621,446$3.65
$78.21kSell
Jack W. CallicuttChief Financial Officer2026-01-0525,732$3.90
$100.30kSell
Joel LewisPresident and CEO2026-01-0556,332$3.88
$218.57kSell
Joel LewisPresident and CEO2026-01-0527,731$3.91
$108.35kSell
Khurram JamilChief Medical Officer2026-01-0525,499$3.90
$99.40kSell
Joel LewisPresident and CEO2026-01-0218,571$4.20
$77.94kSell

1 of 13

GALT insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when GALT insiders and whales buy or sell their stock.

GALT Shareholders

What type of owners hold Galectin Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
10x Fund LP33.82%22,271,880$56.13MInsider
James C. Czirr31.91%21,015,907$52.96MInsider
Rod D. Martin18.31%12,057,197$30.38MInsider
Richard E. Uihlein15.73%10,360,386$26.11MInsider
David Platt12.78%8,418,743$21.22MInsider
Vanguard Capital Management LLC2.99%1,966,542$4.96MInstitution
Marshall Wace LLP1.85%1,219,912$3.07MInstitution
Osaic Holdings Inc1.70%1,122,670$2.83MInstitution
Joel Lewis1.27%836,592$2.11MInsider
Blackrock Inc1.21%799,237$2.01MInstitution

1 of 3

GALT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
GALT15.44%84.56%Net Selling
HRTX55.60%44.40%Net Buying
OKUR48.14%51.86%Net SellingNet Selling
IMUX78.03%21.97%Net Buying
PLX10.86%89.14%Net Buying
View Top Biotech Stocks

Galectin Therapeutics Stock Ownership FAQ

Who owns Galectin Therapeutics?

Galectin Therapeutics (NASDAQ: GALT) is owned by 21.06% institutional shareholders, 115.40% Galectin Therapeutics insiders, and 0.00% retail investors. 10x Fund LP is the largest individual Galectin Therapeutics shareholder, owning 22.27M shares representing 33.82% of the company. 10x Fund LP's Galectin Therapeutics shares are currently valued at $56.13M.

If you're new to stock investing, here's how to buy Galectin Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.